International Center for Public Health (ICPH) 225 Warren Street Room E250D
Phone: (973) 972-2246
University Hospital, Newark
Insurance Participation: with Provider Number (where applicable) The information below is subject to change and should not be relied upon until after
it is verified with the insurance company. In addition, psychiatric providers should
be contacted directly for information on their participation with managed care and
Dr. Xie received her M.D. from the University of Texas in San Antonio, completed Internal Medicine
residency training at Oregon Health Sciences University, and clinical and research fellowship in
Infectious Diseases at the National Institutes of Health. Her interest in tuberculosis grew after a
memorable clinical encounter during residency highlighted the outdated diagnostics and therapies
used to combat the morbid, globally-prevalent disease. Dr Xie joined Rutgers NJMS in 2019 after
receiving a NIAID K22 and Gates Foundation pilot award. Her research group in the Center of
Emerging Pathogens, Rutgers NJMS works on developing and optimizing clinical tools to study,
diagnose, and treat tuberculosis.
American Board of Internal Medicine - Infectious Diseases
American Board of Internal Medicine - Internal Medicine
MD, 2009, University of Texas Medical School, San Antonio
Licensure & Certification
Medical Licensure New Jersey
Xie YL, Cronin WA, Proschan M, Oatis R, Cohn S, Curry SR, Golub JE, Barry CE 3rd, Dorman SE.
Transmission of Mycobacterium tuberculosis From Patients Who Are Nucleic Acid Amplification Test
Negative. Clin Infect Dis. 2018 Nov 13;67(11):1653-1659
Xie YL, Chakravorty S, Armstrong DT, Hall SL, Via LE, Song T, Yuan X, Mo X, Zhu H, Xu P, Gao Q, Lee M,
Lee J, Smith LE, Chen RY, Joh JS, Cho Y, Liu X, Ruan X, Liang L, Dharan N, Cho SN, Barry CE 3rd, Ellner
JJ, Dorman SE, Alland D. Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. N
Engl J Med. 2017 Sep 14;377(11):1043-1054.
Xie Research Group
The Xie research group is focused on clinical and translational studies that lay the groundwork for new
tuberculosis (TB) diagnostic approaches and the development of high-resolution clinical imaging tools
for precision medicine research in TB.
With the advent of highly-sensitive diagnostics that challenge the detection limit of gold standard
culture, our team is leading efforts to elucidate the biology and natural history of culture-negative and
paucibacillary TB through integrated studies which overlay epidemiologic, clinical, and laboratory
components. Additionally, we work with a consortium of investigators to evaluate new TB diagnostics
in multi-center clinical accuracy studies.
Our team also explores imaging biomarkers which characterize the inter- and intra- individual
heterogeneity of TB disease that are not captured by dichotomous diagnostic test results. We seek to
train clinical imaging modalities (eg. PET-CT) to recognize and link high-resolution biologic features
(eg. histopathology), clinical phenotypes, and treatment responses. Our goal in this area is to develop
a precision medicine research tool which compares the underlying pathology and therapeutic effects
(host-directed or antibiotics) among patients with different manifestations of TB disease.